Transcriptomic Analysis Predicts Survival and Sensitivity to Anticancer Drugs of Patients with a Pancreatic Adenocarcinoma (original) (raw)

Scientific rationale for integrative and personalised strategies for pancreatic ductal adenocarcinoma management

Korhan Peyda

2017

View PDFchevron_right

The Evolving Understanding of the Molecular and Therapeutic Landscape of Pancreatic Ductal Adenocarcinoma

Jaswinder Samra

Diseases, 2018

View PDFchevron_right

A rapid in vivo screen for pancreatic ductal adenocarcinoma therapeutics

yalda zolghadri

Disease Models & Mechanisms, 2015

View PDFchevron_right

Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy

Lakshmi Jakkula

Nature Medicine, 2011

View PDFchevron_right

Pancreatic cancer - lessons from the past decade

Ekin Demir

Indian Journal of Medical and Paediatric Oncology, 2015

View PDFchevron_right

Short report – Lethal and aggressive pancreatic cancer: molecular pathogenesis, cellular heterogeneity, and biomarkers of pancreatic ductal adenocarcinoma

Kannan Subbaram

Kannan Subbaram, 2022

View PDFchevron_right

Molecular Characteristics of Pancreatic Ductal Adenocarcinoma

Niki Ottenhof

Pathology Research International, 2011

View PDFchevron_right

Targeted Therapies for Pancreatic Cancer and Hurdles Ahead

Minela Aslan

Anticancer Research

View PDFchevron_right

Pathophysiology of Pancreatic Adenocarcinoma

Neharika Gupta

2020

View PDFchevron_right

Pancreatic Adenocarcinoma: Current Therapies and Challenges

Bessi Qorri, Myron Szewczuk

View PDFchevron_right

Advances in Pancreatic Ductal Adenocarcinoma Treatment

Andrew Hendifar

Cancers, 2021

View PDFchevron_right

Treatment optimization of locally advanced and metastatic pancreatic cancer (Review)

Helder Mansinho

International Journal of Oncology, 2021

View PDFchevron_right

Druggable Targets in Pancreatic Adenocarcinoma

Enrico Mini

Forum on Immunopathological Diseases and Therapeutics, 2015

View PDFchevron_right

A comprehensive review of pancreatic cancer and its therapeutic challenges

Johan Fagman

Aging

View PDFchevron_right

Novel approaches in the management of pancreatic ductal adenocarcinoma: potential promises for the future

Gaurav Goel

Journal of Hematology & Oncology, 2015

View PDFchevron_right

Emerging therapies for pancreatic ductal carcinoma

Shaker Mousa

Journal of Solid Tumors, 2016

View PDFchevron_right

Upcoming Revolutionary Paths in Preclinical Modeling of Pancreatic Adenocarcinoma

Mirna Swayden

Frontiers in Oncology

View PDFchevron_right

Sa1367 – Half of Sporadic Pancreatic Ductal Adenocarcinoma Patients Receive Minimal Or No Treatment: A Population-Based Study At a Tertiary Care Center

Ayush Sharma

Gastroenterology, 2019

View PDFchevron_right

Concerted cell and in vivo screen for pancreatic ductal adenocarcinoma (PDA) chemotherapeutics

Thomas Wilkie

Scientific Reports

View PDFchevron_right

Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma

Arnav Mehta

CA: A Cancer Journal for Clinicians, 2020

View PDFchevron_right

Cancer Models to Defeat Therapy Resistance in Pancreatic Ductal Adenocarcinoma

Britney He

Spring 2021, 2021

View PDFchevron_right

Molecular biology of pancreatic cancer

Andrew Lowy

Clinical and Translational Oncology, 2008

View PDFchevron_right

State of the art biological therapies in pancreatic cancer

Riccardo Casadei

World journal of gastrointestinal oncology, 2016

View PDFchevron_right

Exploring the Complementarity of Pancreatic Ductal Adenocarcinoma Preclinical Models

Nicolas Fraunhoffer

Cancers

View PDFchevron_right

Consensus Report of the National Cancer Institute Clinical Trials Planning Meeting on Pancreas Cancer Treatment

Joel Tepper

Journal of Clinical Oncology, 2009

View PDFchevron_right

Locally Advanced Pancreatic Ductal Adenocarcinoma: Challenges and Progress

Luigi Pugliese

2020

View PDFchevron_right

Key drug-targeting genes in pancreatic ductal adenocarcinoma

Meena Sakharkar

Genes & Cancer, 2021

View PDFchevron_right

Establishment of a pancreatic adenocarcinoma molecular gradient (PAMG) that predicts the clinical outcome of pancreatic cancer

stephane garcia

2020

View PDFchevron_right

A Pilot Trial of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Ductal Adenocarcinoma

Farrukh Shezad

Journal of Pancreatic Cancer

View PDFchevron_right